A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction

• Status: Recruiting
• Trial end date: 2025-04-30

Summary

This is a phase II, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of perioperative trastuzumab+XELOX with / without atezolizumab in participants eligible for surgery with locally advanced HER2-positive gastric cancer or adenocarcinoma of GEJ.

• Phase: Phase 2

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: Atezolizumab; Capecitabine; Oxaliplatin; Trastuzumab